Literature DB >> 15742635

Aujeszky's disease vaccination and differentiation of vaccinated from infected pigs.

M Pensaert1, G Labarque, H Favoreel, H Nauwynck.   

Abstract

In this paper, the use of a glycoprotein E (gE)-deleted vaccine to eradicate Aujeszky's disease virus (ADV) or pseudorabies virus in swine is described. In regions where there is a dense population of swine, ADV is highly prevalent and intensive vaccination with such a marker vaccine has resulted, in several countries, in a decrease of the field virus prevalence to a sufficiently low level so that culling becomes economically feasible. The evolution in the reduction of circulating field virus can be followed at herd and/or population level by serological monitoring for antibodies against gE, using commercially available enzyme-linked immunosorbent assays. To be successful, other measures besides the vaccination in itself are important, such as the proper use and administration of the vaccine, repeated boosters, prevention of introduction of gE-positive animals and restriction in the movement of animals from gE-positive herds. When pockets of infection remain, intensifying the vaccination may be needed. Culling of remaining gE-positive animals, particularly breeders, is usually necessary. Some European Union (EU) member states have become ADV-free using this approach. Others are still working at it. The success is often dependent on whether or not a good discipline exists. The disease situation in the different EU member states is described. In ADV-free regions with dense swine populations at risk, it is advisable not to stop the vaccination too soon, particularly when the infection status in neighbouring countries or trade partners is not equally good.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15742635

Source DB:  PubMed          Journal:  Dev Biol (Basel)        ISSN: 1424-6074


  6 in total

Review 1.  Current status of veterinary vaccines.

Authors:  Els N T Meeusen; John Walker; Andrew Peters; Paul-Pierre Pastoret; Gregers Jungersen
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

2.  Bartha-K61 vaccine protects nursery pigs against challenge with novel european and asian strains of suid herpesvirus 1.

Authors:  Konstantinos V Papageorgiou; Margarita Michailidou; Ioannis Grivas; Evanthia Petridou; Efthymia Stamelou; Konstantinos Efraimidis; Lei Chen; Trevor W Drew; Spyridon K Kritas
Journal:  Vet Res       Date:  2022-06-22       Impact factor: 3.829

3.  Expression and purification of Suid Herpesvirus-1 glycoprotein E in the baculovirus system and its use to diagnose Aujeszky's disease in infected pigs.

Authors:  María Soledad Serena; Christoph Geisler; Germán Ernesto Metz; Santiago Gerardo Corva; Eduardo Carlos Mórtola; Alejandra Larsen; Donald L Jarvis; María Gabriela Echeverría
Journal:  Protein Expr Purif       Date:  2013-04-28       Impact factor: 1.650

Review 4.  Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.

Authors:  Virginia Aida; Vasilis C Pliasas; Peter J Neasham; J Fletcher North; Kirklin L McWhorter; Sheniqua R Glover; Constantinos S Kyriakis
Journal:  Front Vet Sci       Date:  2021-04-15

5.  Assessment of an Aujeszky's Disease Control Strategy in a Highly Prevalent Pig Farm Based on Systematic Vaccination With an Inactivated gE-Negative Marker Vaccine.

Authors:  María N Aznar; Fernando A Bessone; Rodrigo Segurado; Sergio J Duffy
Journal:  Front Vet Sci       Date:  2022-04-22

6.  Enhanced Immune Responses in Mice Induced by the c-di-GMP Adjuvanted Inactivated Vaccine for Pseudorabies Virus.

Authors:  Liting Hou; Xiaoming Yu; Yuanyuan Zhang; Luping Du; Yuanpeng Zhang; Haiwei Cheng; Qisheng Zheng; Jin Chen; Jibo Hou
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.